Levy R., Reagan P.M., Friedberg J.W., Bartlett N.L., Gordon L.I.,Leung A., Peterkin J., Xing B., Coffman R., Janssen R., Candia A.,Khodadoust M., Frank M.J., Long S.R., Czerwinski D.K., Chu M.SD-101, a novel class C CpG-oligodeoxynucleotide (ODN) toll-likereceptor 9 (TLR9) agonist, given with low dose radiation for untreatedlow grade B-cell lymphoma: interim results of a phase 1/2trial. Here, TLR9 is linked to B-cell non-Hodgkin lymphoma.